1 on to healthy controls and disease controls (Duchenne's Muscular Dystrophy).

2 filtration of numbers of T cells compared to Duchenne's muscular dystrophy.

3 mote muscle regeneration for patients having Duchenne's muscular dystrophy.

4 donor nuclei in the muscle of a patient with Duchenne's muscular dystrophy.

5 gene to skeletal muscle in six patients with Duchenne's muscular dystrophy.

6 f this pseudotyped virus in a mouse model of Duchenne's muscular dystrophy also demonstrated signific

7 s must be used with caution in children with Duchenne's muscular dystrophy as hyperkalemia may occur

8 rophin and the devastating muscle failure of Duchenne's muscular dystrophy (DMD) has been well establ

9                                              Duchenne's muscular dystrophy (DMD) is a fatal neuromusc

10 ue of dystrophin, the protein product of the Duchenne's muscular dystrophy (DMD) locus.

11 s a strategy for reversing muscle wasting in Duchenne's muscular dystrophy (DMD) without resorting to

12 sm for the clinical sparing of EOMs noted in Duchenne's muscular dystrophy (DMD).

13 lications when administered to children with Duchenne's muscular dystrophy: hyperkalemia in younger c

14 s the mdx phenotype to more closely resemble Duchenne's muscular dystrophy in humans.

15 nished Homer 1 expression in mouse models of Duchenne's muscular dystrophy suggests that loss of Home

16                              Both in JDM and Duchenne's muscular dystrophy the proportion of FOXP3+ T

17 studies in the mdx mouse, an animal model of Duchenne's muscular dystrophy, which indicate that the i